Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma:A case report and review of literature  

作　　者：Xiao-Dong Peng Zhen-Yu You Lian-Xiang He Qi Deng 

机构地区：[1]Department of Cancer,The First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China [2]Department of Medical Affairs,Guangzhou Gloria Bioscience Co.,Ltd.,Beijing 100005,China

出　　处：《World Journal of Clinical Cases》2023年第22期5296-5302,共7页世界临床病例杂志

摘　　要：BACKGROUND Malignant peritoneal mesothelioma(MPeM)is a rare cancer with a poor prognosis at advanced stage,and the standard first-line treatment for inoperable patients is chemotherapy.Although combining programmed cell death 1(PD-1)inhibitors with chemotherapy is generally considered safe and effective in several malignant solid tumors,there are few reports regarding initial immunochemotherapy in advanced MPeM.CASE SUMMARY Here,to our knowledge,we present the first case of a patient with epithelioid subtype MPeM,who was treatment-naïve and benefited from initial PD-1 inhibitor plus standard chemotherapy with a prolonged progression-free survival(PFS)and good tolerance.A 49-year-old man was admitted to our hospital for a persistent burning sensation in the abdomen.Computed tomography revealed a solid mass in the lower abdomen,which was subsequently diagnosed histologically as epithelioid subtype MPeM by core needle biopsy.The patient received eight cycles of pemetrexed 800 mg(day 1),cisplatin 60/50 mg(day 1–2),and zimberelimab(PD-1 inhibitor)240 mg(day 1)every 3 wk.He achieved significant reduction of peritoneal tumors with remarkable improvement in symptoms.The best tumor response was partial remission with a final PFS of 7 mo.No immunerelated adverse event occurred during the combination treatment.CONCLUSION The outcome of the present case demonstrates the promising anti-tumor activity of immunochemotherapy to treat inoperable MPeM in the future.

关 键 词：Malignant peritoneal mesothelioma Immune checkpoint inhibitors IMMUNOTHERAPY Zimberelimab CHEMOTHERAPY Case report 

分 类 号：R735.5[医药卫生—肿瘤]